PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Brain Behav Immun. Author manuscript; available in PMC Feb 1, 2010.
Published in final edited form as:
PMCID: PMC2652747
NIHMSID: NIHMS95918
Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression
Eric V. Yang,1,2 Seung-jae Kim,2 Elise L. Donovan,2 Min Chen,2 Amy C. Gross,2 Jeanette I. Webster Marketon,2,4,5 Sanford H. Barsky,3,6 and Ronald Glaser1,2,3,4
1 Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University Medical Center, Columbus, OH 43210
2 Institute for Behavioral Medicine Research, The Ohio State University Medical Center, Columbus, OH 43210
3 Comprehensive Cancer Center, The Ohio State University Medical Center, Columbus, OH 43210
4 Department of Internal Medicine, The Ohio State University Medical Center, Columbus, OH 43210
5 Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, The Ohio State University Medical Center, Columbus, OH 43210
6 Department of Pathology, The Ohio State University Medical Center, Columbus, OH 43210
Corresponding author: Ronald Glaser, Ph.D., Institute for Behavioral Medicine Research, The Ohio State University, 2175 Graves Hall, 333 W. 10th Avenue, Columbus, OH 43210, Phone: (614) 292-5526, Fax: (614) 292-1011, e-mail: ronald.glaser/at/osumc.edu
Studies suggest that stress can be a co-factor for the initiation and progression of cancer. The catecholamine stress hormone, norepinephrine (NE), may influence tumor progression by modulating the expression of factors implicated in angiogenesis and metastasis. The goal of this study was to examine the influence of NE on the expression of VEGF, IL-8, and IL-6 by the human melanoma cell lines, C8161, 1174MEL, and Me18105. Cells were treated with NE and levels of VEGF, IL-8, and IL-6 were measured using ELISA and real-time PCR. The expression of β-adrenergic receptors (β-ARs) mRNA and protein were also assessed. Finally, immunohistochemitry was utilized to examine the presence of β1- and β2-AR in primary and metastatic human melanoma biopsies. We show that NE treatment upregulated production of VEGF, IL-8, and IL-6 in C8161 cells and to a lesser extent 1174MEL and Me18105 cells. The upregulation was associated with induced gene expression. The effect on C8161 cells was mediated by both β1- and β2-ARs. Furthermore, 18 of 20 melanoma biopsies examined expressed β2-AR while 14 of 20 melanoma biopsies expressed β1-AR. Our data support the hypothesis that NE can stimulate the aggressive potential of melanoma tumor cells, in part, by inducing the production VEGF, IL-8, and IL-6. This line of research further suggests that interventions targeting components of the activated sympathetic-adrenal medullary (SAM) axis, or the utilization of β-AR blocking agents, may represent new strategies for slowing down the progression of malignant disease and improving cancer patients’ quality of life.
Keywords: psychological stress, norepinephrine, melanoma, cytokines, angiogenesis, vascular endothelial growth factor, interleukin (IL)-8, IL-6
There is evidence that psychological factors can affect the incidence and progression of some cancers (Kruk and Aboul-Enein, 2004; Metcalfe et al., 2007; Reiche et al., 2004; White et al., 2007). Data obtained from studies using animal models support the hypothesis that stress could be a co-factor (Riley, 1975; Saul et al., 2005). Studies in the field of psychoneuroimmunology have shown that psychological stress can affect many aspects of innate and specific cellular immune responses mediated by the endocrine system through bi-directional interactions (Ader, 2007; Rabin, 1999).
Recent studies suggest that stress can also have a direct effect on tumor progression independent of the dysregulation of the immune system. Work from our laboratory and others have shown that vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs) are factors that can be modulated by catecholamine hormones. Studies by Sood, Lutgendorf and others have shown that norepinephrine (NE) and epinephrine (E) may influence the progression of ovarian cancer by modulating the expression of MMPs and the angiogenic cytokine, VEGF, in ovarian cancer cells (Lutgendorf et al., 2003; Sood et al., 2006; Thaker et al., 2007). The ability of NE to promote progression of other cancers is supported by our recent work showing that NE enhanced the invasive and pro-angiogenic properties of nasopharyngeal carcinoma (NPC) cells by stimulating the secretion of VEGF, MMP-2, and MMP-9 in vitro (Yang et al., 2006). In these two studies it was shown that β-adrenergic receptors (ARs) mediated the production of these proteins. We have further suggested that this property of NE is not restricted to solid tumors through our results showing that NE can upregulate levels of VEGF proteins in culture supernatants of multiple myeloma-derived cell lines (Yang et al., 2008). These observations support the hypothesis that stress-associated activation of the sympathetic-adrenal medullary (SAM) axis can promote tumor progression, in part, by modulating the expression of pro-angiogenic and pro-metastatic factors.
Several clinical studies provide examples of the role that stressors may play as a co-factor for enhancing melanoma tumor progression (Temoshok et al., 1985). Such relationship between behavior and melanoma progression was explored in studies by Fawzy and co-workers (Canada et al., 2005; Fawzy et al., 2003; Fawzy et al., 1993). They found that participation in a psychiatric intervention that enhances effective coping and reduces affective distress had beneficial effects on melanoma progression and was positively correlated with survival (Fawzy et al., 2003; Fawzy et al., 1993).
The hypothesis that psychological stress can affect melanoma progression is further supported by a study using a B16 melanoma mouse tumor model. Mice that were either housed in a crowded condition or in isolation exhibited an increase in tumor growth which was completely abrogated by the oral administration of the β-adrenergic antagonist propranolol (Hasegawa and Saiki, 2002). Although factors involved in the progression of melanoma have been well described, the role(s) these psychological factors play in modulating the growth and spread of tumors is not fully understood.
Tumor angiogenesis is a critical step in the progression of cancer, including melanoma, allowing tumors to grow beyond 1–2 mm in diameter (Gimbrone et al., 1972). The expression of VEGF, interleukin (IL)-8, and IL-6 have been shown to be important for this process (Nilsson et al., 2005; Tammela et al., 2005; Yuan et al., 2005). Therefore, the goal of this study is to examine the impact of the catecholamine stress hormone NE on the modulation of expression of VEGF, IL-8 and IL-6 in three human melanoma cell lines, C8161, 1174MEL, and Me18105.
2.1 Cell Lines and Culture Conditions
Three human melanoma cell lines, C8161, 1174MEL, and Me18105, were used in this study. C8161 is a well-characterized human cutaneous malignant melanoma cell line established from an abdominal wall metastasis. These tumor cells metastasize after orthotopic injection into athymic nude mice (Welch et al., 1991). 1174MEL was derived from a lymph node metastasis in a patient who exhibited clinical responses to T cell-based immunotherapy (Restifo et al., 1996). Me18105 was generated from an unspecified metastatic lesion of a melanoma patient (Hicklin et al., 1998). Cells were maintained in complete medium composed of RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), L-glutamine, and 1X antibiotic-antimycotic (Invitrogen Life Technologies, Carlsbad, CA) at 37°C in a humidified atmosphere with 5% CO2. For NE treatments, serum-free conditions were utilized in order to eliminate the possible influence of factors that can be found in fetal calf serum on the effects of NE on the human melanoma cell lines. Cells were seeded in 6-well plates, with 2 × 105 cells/well in 2 ml of media, and cultured for 1 day in serum-free media in order to allow the cells to adapt to this condition. Cells were treated with NE (Sigma-Aldrich Co., St. Louis, MO) by replacing the media with 2 ml serum-free media containing 0, 0.1, 1, and 10 μM NE. To assess the effects of NE on levels of VEGF, IL-8, and IL-6, culture supernatants were collected at various time points, centrifuged, and stored at −80°C until assayed by ELISA. Cells were homogenized in TRIzol reagent and stored at −80°C until assayed by real-time PCR.
2.2 Determination of VEGF, IL-8 and IL-6 Protein Concentrations in Culture Supernatants
The concentrations of VEGF, IL-8 and IL-6 were measured using Human Quantikine ELISA Kits (R&D Systems, Minneapolis, MN) following the manufacturer’s protocol. The resultant color was read at 450 nm using a Labsystems Multiskan MCC/340 plate reader. The concentrations of the protein of interest in a sample were determined by interpolation from a standard curve.
2.3 Assesment of cell proliferation using [3H]-thymidine incorporation
The C8161, 1174MEL and Me18105 cells were seeded in 200 μl complete medium in 96-well plates at a density of 7000 cells/well and incubated for 24 hours. The medium was removed and replaced with serum-free medium. The cells were cultured for 1 day in serum-free media, and treated with NE at 0, 0.1, 1, and 10 μM for 24 hours. Six hours prior to the end of the 24 hour treatment, 0.5 μ Ci [3H]-thymidine (2 Ci/mmol) was added and the cells were incubated at 37°C. After 6 hours of incubation, cells were trypsinized and harvested onto glass fiber filter papers using a PHD Cell Harvester (Cambridge Technology). Each glass fiber filter was placed into a scintillation tube with 4 ml of scintillation cocktail (Bio Safe II, Research Products International Corp.). The amount of [3H]-thymidine incorporated was quantified using a LS60001C liquid scintillation counter (Beckman).
2.4 Real-time PCR Assessment of VEGF, IL-8, and IL-6 Gene Expression
We utilized real-time RT-PCR on NE-treated cell lines in order to determine the effect of NE on VEGF, IL-8, and IL-6 gene expression. Total RNA from cultured cells was isolated using TRIzol reagent following the manufacturer’s instructions (Invitrogen Life Technologies, Carlsbad, CA). First strand cDNAs were synthesized using random primers and Superscript II RNase H reverse transcriptase (Invitrogen Life Technologies). Levels of VEGF, IL-8, and IL-6 mRNA were analyzed using the Taqman Gene Expression Assays (Assay IDs: VEGF, Hs00173626_m1; IL-8, Hs00174103_m1; IL-6, Hs00174131_m1; Applied Biosystems, Foster City, CA). The housekeeping gene GAPDH was analyzed using the Taqman Human GAPDH Endogenous Control Reagent (Assay ID: 4326317E, Applied Biosystems) and was used as an internal positive control. All TaqMan Gene Expression Assays used in our analyses utilize primer sequences that span across two adjacent exons of the target genes and are thus specific for mRNAs. Levels of each target mRNA were measured with TaqMan fluorogenic probes listed above, and amplified using the 7300 Real-Time PCR system (Applied Biosystems). Reactions were performed with 12.5 μl TaqMan Universal Master Mix and 1.25 μl of the specific primer adjusted to a final volume of 25 μl with water. The cycler conditions were as follows: incubation for 2 min at 50 °C followed by another incubation step at 95 °C for 10 min, afterwards 15 s at 95 °C and 1 min at 60 °C for 40 cycles. The levels of expression of VEGF, IL-8, and IL-6 mRNA in each sample were normalized to the GAPDH mRNA levels. The relative expression of mRNA species was calculated using the comparative CT method as described by the manufacturer (see User bulletin #2 Applied Biosystems, P/N 4303859, 1997) (Livak and Schmittgen, 2001).
In order to test the role of mRNA stability in the NE-dependent regulation of VEGF, IL-8, and IL-6 mRNA levels in C8161 cells, the effect of actinomycin D, an inhibitor of de novo transcription, on mRNA levels was assessed. C8161 cells were grown in the presence of 5 μg/ml actinomycin D (Sigma Aldrich, St. Louis, MO) and 10 μM NE for 1 or 2 hours. Total RNA was isolated and the levels of VEGF, IL-8, and IL-6 mRNA were measured using real-time PCR as above.
2.5 Analysis of β-adrenergic receptor expression by real-time PCR and Western blotting
The expression of ADRB1 and ADRB2 mRNA (encoding for β1- and β2-AR, respectively) in C8161, 1174MEL and Me18105 cells were assayed using Taqman Gene Expression Assays (Assay IDs: Hs00265096_s1 and Hs00240532_s1, respectively) as above. The expression of β1- and β2-AR proteins was assessed using Western blotting as previously described (Yang et al., 2006).
2.6 Assessment of Signaling Pathways
In order to examine the signaling pathway involved in the NE-dependent effects we treated C8161 cells with a variety of agonists and antagonists. Blocking experiments were first performed with the β-AR antagonist propranolol and the α-AR antagonist phentolamine. Propranolol (1 μM) or phentolamine (10 μM) were added to the cell cultures 30 min before adding 10 μM NE.
Since the cAMP-PKA signaling pathway has been suggested to mediate the effects of NE on ovarian cancer cells to upregulate VEGF (Thaker et al., 2006), a possible role of this pathway for the NE-dependent effects on C8161 cells was tested. C8161 cells were treated with the β-AR agonist isoproterenol, β1-AR agonist dobutamine, β2-AR agonist terbutaline, adenylate cyclase agonist forskolin, the selective activator of the cAMP receptor Exchange Protein directly activated by cAMP (EPAC) 8-(4-chlorophenylthio)-2′-O-methyladenosine-3′, 5′-cyclic monophosphate (8-CPT), the selective activator of the cAMP-dependent protein kinase (PKA) N6-Benzoyladenosine-3′, 5′-cyclic monophosphate (6-Bnz-cAMP), and the PKA inhibitors, H-89 and myristoylated protein kinase inhibitor (PKI). C8161 cells were grown in serum-free media alone, 10 μM NE, 10 μM isoproterenol, 10 μM dobutamine, 10 μM terbutaline, 10 μM forskolin, 100 μM 8-CPT, or 100 μM 6-Bnz-cAMP. To assess the effect of the PKA inhibitors, C8161 cells were first treated with H-89 or PKI for 30 minutes prior to the addition of 10 μM NE. Cells were collected after a 1 hour incubation to measure IL-8 and IL-6 mRNA and 2 hours for VEGF gene expression analysis. Total RNA was isolated and the levels of VEGF, IL-8, and IL-6 mRNA were measured using real-time PCR as described.
Propranolol and phentolamine were purchased from Fisher Scientific (Waltham, MA); isoproterenol, dobutamine and terbutaline from Sigma (St. Louis, MO); forskolin, 6-Bnz-cAMP, and 8-CPT from Axxora Life Sciences (San Diego, CA); H-89 and myristoylated PKI from Calbiochem (La Jolla, CA).
2.7 Immunohistochemical analysis of β1- and β2-AR in melanoma biopsies
Ten biopsies of primary melanoma (nodular, superficial spreading and desmoplastic) and 10 biopsies of metastatic melanoma (lymph node and visceral metastasis) were obtained from the Archives of the Pathology Department and examined for β2-AR expression as previously described (Yang et al., 2006). Additionally, melanoma biopsies were examined for β1-AR expression using the V-19 rabbit anti-β1-AR polyclonal antibody (sc-568) (Santa Cruz Biotechnology, Santa Cruz, CA). A surgical pathologist evaluated each biopsy.
2.8 Statistical Analysis
Experiments were performed in duplicate and repeated at least once. Results were expressed as the mean ± s.e.m. Changes in VEGF, IL-8, and IL-6 protein levels were evaluated with an analysis of variance (ANOVA) with an LSD post-hoc test using SPSS v16.0 (SPSS Science, Chicago, IL). P ≤ 0.05 was considered significant.
3.1 VEGF, IL-8, and IL-6 protein levels in culture supernatants of NE-treated C8161, 1174MEL, and Me18105 cells
We observed a NE dose-dependent and time-dependent increase in VEGF in culture supernatants of C8161 cells with the 6-hour treatment yielding the greatest effect (F(3,26) = 5.282, P < 0.05). Treatments of C8161 cells with 1 and 10 μM NE for 6 hours resulted in increases to 176.61 ± 35.70 % (from 59.41 ± 9.21 pg/ml to 112.67 ± 32.86 pg/ml) (P = 0.001) and 249.79 ± 26.00% (from 59.41 ± 9.21 pg/ml to 151.05 ± 30.77 pg/ml) (P < 0.001) of control levels, respectively (Fig. 1A).
Figure 1
Figure 1
NE differentially modulates the levels of VEGF, IL-8, and IL-6 protein in culture supernatants of C8161 (A, B, and C), 1174MEL (D and E), and Me18105 (F and G) cells after treatment with NE. Levels of protein in culture supernatants were measured after (more ...)
Likewise, IL-8 protein levels in culture supernatants of C8161 cells increased in response to exposure to NE. Upregulation was observed at the 1 hour time point which approached significance (F(3, 12) = 3.427, P = 0.052). Significant upregulation was also observed after 3, 6, and 24 hours of treatment (F(3, 28) = 3.613, P < 0.05, F(3, 31) = 2.984, P < 0.05, and F(3, 26) = 10.517, P < 0.001, respectively). Peak stimulation was observed after treatment of C8161 cells with 10 μM NE for 6 hours with IL-8 protein levels increasing to 315.55 ± 64.72% of control (from 141.46 ± 41.48 pg/ml to 570.18 ± 313.82 pg/ml) (P < 0.05) (Fig. 1B).
It is of interest that the greatest change was observed with levels of IL-6 protein. For example, although treatment of C8161 cells with 0.1 μM NE for 6 hours did not significantly stimulate IL-6 protein levels, treatment with 10 μM resulted in a robust increase in IL-6 protein level of up to at least 3186.34 ± 1035.33% of control level (increasing from below the detectable limit of 3.12 pg/ml to 99.41 ± 32.30 pg/ml) (P < 0.05) (Fig. 1C).
Overall, the 1174MEL and Me18105 cells exhibited NE-dependent upregulation of VEGF, and IL-8 proteins similar to C8161 cells, albeit to a lesser extent. Treatment of 1174MEL cells with 10 μM NE for 24 hours resulted in the greatest increase in the level of VEGF up to 186.76 ± 30.22% of control VEGF levels (increasing from 208.29 ± 64.63 pg/ml to 309.59 ± 52.42 pg/ml) (P = 0.001) (Fig. 1D), while IL-8 levels increased up to 345.87 ± 29.70% of control levels in the same treatment conditions (increasing from 236.72 ± 88.93 pg/ml to 693.93 ± 214.86 pg/ml) (P < 0.001) (Fig. 1E). Me18105 cells did not exhibit as great a response to NE exposure; treatment with 10 μM NE for 6 hours resulted in an increase in VEGF levels of up to 194.63 ± 22.18% of control levels (increasing from 59.29 ± 28.26 pg/ml to 61.69 ± 20.95 pg/ml) (P < 0.001) (Fig. 1F). On the other hand, IL-8 levels decreased in culture supernatants in response to NE treatment with levels at 66.50 ± 6.61% of control after treatment with 10 μM NE for 24 hours (81.33 ± 16.98 pg/ml in untreated controls vs. 53.37 ± 10.13 pg/ml in treated cells) (P < 0.001) (Fig. 1G). Furthermore, these two cell lines did not produce detectable levels of IL-6 protein in untreated and NE treated culture supernatants.
3.2 The effect of NE on the proliferation of melanoma cells
We subsequently examined whether a NE-dependent effect on cell proliferation is a factor in the observed increase in VEGF, IL-8, and IL-6 protein levels. Using [3H]-thymidine incorporation, no significant dose-dependent increase in cell proliferation was observed after exposure of the human melanoma cell lines to NE (Fig. 2). The only significant change observed was a decrease in [3H]-thymidine incorporation after treatment of C8161 and 1174 MEL cells with 10 μM NE. These data suggest that a NE-dependent stimulation of proliferation is not a factor in the modulation of the pro-angiogenic protein levels in culture supernatants.
Figure 2
Figure 2
Representative [3H]-thymidine incorporation assessing the effect of NE on cell proliferation. Cell proliferation was measured using [3H]-thymidine incorporation (see Materials and Methods) after C8161, 1174MEL, and Me18105 cells were treated with 0, 0.1, (more ...)
3.3 NE upregulates VEGF, IL-8, and IL-6 gene expression in C8161 cells
To further elucidate the mechanism involved in the modulation of VEGF, IL-8, and IL-6 protein levels in culture supernatants of C1861 cells we examined the effect of exposure to NE on the transcription of these genes. As measured by real-time PCR, we observed that treatment of C8161 cells with NE upregulated the levels of VEGF, IL-8, and IL-6 mRNA with IL-6 mRNA levels being most greatly upregulated. This is consistent with the observed robust increase in IL-6 protein levels after exposure to NE. Treatment of C8161 cells with 10 μM NE resulted in a significant increase of VEGF mRNA levels which peaked after 2 hours of treatment (Fig. 3A). In contrast to VEGF and IL-6 mRNA, upregulation of IL-8 mRNA levels were observed with treatment with 0.1 μM NE. The induction levels of IL-8 mRNA in C8161 cells peaked after 1 hour of treatment and decreased thereafter (Fig 3B) with maximum levels of IL-8 mRNA observed after treatment of C8161 cells with 1 μM NE. Finally, NE was also observed to more efficiently upregulate the level of IL-6 mRNA in cultures of C8161 cells. Whereas the levels of mRNA in cultures exposed to 0, 0.1, and 1 μM NE remained low, treatment with 10 μM NE resulted in a marked burst in IL-6 mRNA levels peaking after 1 hour of treatment with levels decreasing thereafter (Fig. 3C).
Figure 3
Figure 3
The NE-dependent upregulation of VEGF, IL-8, and IL-6 mRNA levels in C8161 cells is mainly through the stimulation of transcription and not through increased mRNA stability. Representative real-time PCR assay measuring VEGF (A), IL-8 (B), and IL-6 (C) (more ...)
Co-treatment of C8161 cells with 5 μg/ml actinomycin D and 10 μM NE efficiently inhibited the NE-dependent upregulation of VEGF, IL-8, and IL-6 mRNA levels (Fig. 3D, E, F, respectively). These results suggest that the NE-dependent upregulation of VEGF, IL-8, and IL-6 protein in C8161 cells is mainly due to the stimulation of de novo transcriptional activity of these three genes.
3.4 β1- and β2-adrenergic receptors are expressed in human melanoma cell lines
Real-time PCR was utilized to assess the levels of the genes encoding for the β1- and β2-AR (ADRB1 and ADRB2, respectively) expressed in C8161, 1174MEL and Me18105 cells. The representative real-time PCR result indicates that the human melanoma cells used in this study express ADRB1 and ADRB2 mRNA with the 1174MEL cells expressing the most ADRB1 mRNA, followed closely by C8161, and Me18105 expressing the lowest amount (Fig. 4A). C8161 cells expressed the most ADRB2 mRNA (Fig. 4B).
Figure 4
Figure 4
Expression of β1-AR and β2-AR in C8161, 1174MEL and Me18105 melanoma cells. Representative real-time PCR assay measuring ADRB1 (A) and ADRB2 (B) mRNA levels in C8161, 1174MEL and Me18105 cells.
The above differences are further buttressed by the observation that the three human melanoma cells differed in the expression of β1- and β2-AR proteins as shown by Western blotting. Differences in the β1- and β2-AR expression pattern between C8161, 1174MEL and Me18105 cells were observed. Cell lysates from the three cell lines probed for β1-AR revealed a band with an apparent molecular weight of 75 × 103 Mr (Fig. 4C). However, an additional band migrating at about 85 × 103 Mr was observed in 1174MEL and Me18105 cell lysates. On the other hand, C8161, 1174MEL and Me18105 cells exhibited the same pattern of immunoreactive bands when probed for β2-AR but differed in intensity (Fig. 4D); a band at 47 × 103 Mr, consistent with the weight of the unglycosylated protein, and bands migrating around 90 to 100 × 103 Mr, consistent with the size of dimers. Additionally, cells exhibited (at very low abundance) a band at approximately 65 × 103 Mr that is consistent with the glycosylated receptor (Salahpour et al., 2003). β2-AR primarily exists as dimers in C8161 cells. However, it is primarily expressed in the unglycosylated monomeric form in both 1174MEL and Me18105 cells. These bands were not observed in blots incubated with normal rabbit serum (not shown). The significance of the differences in β-AR expression, at the protein and mRNA levels, in C8161 vs. 1174MEL and Me18105 cells is not fully understood.
3.5 Determination of the roles of adrenergic receptors and downstream signaling factors
In an effort to determine whether β-ARs mediate the NE-dependent modulation of VEGF, IL-8, and IL-6 gene expression (Fig. 5A, B, C, respectively) in C8161, 1174MEL, and Me18105 cells, we treated the cells with nonselective AR antagonists. The α-AR antagonist phentolamine efficiently inhibited the NE-dependent stimulation of VEGF, IL-8, and IL-6 gene expression in Me18105 cells. On the other hand, similar treatment of C8161 and 1174MEL cells resulted in an increase in the levels of all three mRNAs. Treatment with the β-AR antagonist propranolol completely abrogated the NE-induced upregulation of VEGF, IL-8, and IL-6 mRNA levels in all three cell lines. These data indicate that the NE-dependent upregulation of VEGF, IL-8, and IL-6 mRNA levels in C8161, 1174MEL, and Me18105 cells is mediated by the β-ARs. Additionally, the above results show that the α-AR mediates the NE-dependent upregulation of these three genes in Me18105 cells.
Figure 5
Figure 5
Assessment of the role of β-adrenergic receptors and the cAMP-PKA signaling pathway. Effect of β-blocker (propranolol) and a-blocker (phentolamine) on the NE-dependent modulation of VEGF, IL-8, and IL-6 mRNA in C8161, 1174MEL, and Me18105 (more ...)
We assessed whether the cAMP-PKA signaling pathway plays a role in the NE-dependent upregulation of VEGF, IL-8, and IL-6 mRNA levels in C8161 cells (Fig. 5D, E, F, respectively). Cells were treated with the β-AR agonist isoproterenol, the β1-AR agonist dobutamine, the β2-AR agonist terbutaline, the adenylate cyclase agonist forskolin, the cAMP analogs, 6-Bnz-cAMP and 8-CPT, and the PKA inhibitors, H-89 and PKI. Treatment with 10 μM NE or 10 μM isoproterenol resulted in significant stimulation of VEGF, IL-8, and IL-6 gene expression supporting the hypothesis that ligation of β-ARs is involved in the observed NE-dependent effect. Furthermore, both dobutamine and terbutaline treatments stimulated VEGF, IL-8, and IL-6 gene expression implicating both β1- and β2-ARs as mediators of the NE-dependent effect. In addition, although treatments with 10 μM forskolin, the adenylate cyclase agonist, resulted in higher levels of VEGF, IL-8, and IL-6 mRNA in C8161 cells, exposure of these cells to 100 μM 8-CPT or 100 μM 6-Bnz-cAMP did not give the same result. Lastly, we observed the differential effects of the PKA inhibitors, H-89 and PKI, on VEGF, IL-8, and IL-6 mRNA levels in NE-treated C8161 cells. Both inhibitors partially abrogated the effect of NE on VEGF gene expression. On the other hand, H-89 was able to completely inhibit the NE-dependent effect on IL-8 and IL-6 gene expression, while PKI failed to exert the same effect. Further studies will need to be performed to further elucidate the role of the cAMP-PKA pathway or alternative pathways in the modulation of VEGF, IL-8, and IL-6 in C8161 cells.
3.6 Melanoma biopsy specimens express the β1- and β2-AR
In order to determine the clinical relevance of our results, we examined all three histological types of primary melanoma tumors including nodular, superficial-spreading and desmoplastic. We also examined lymph node and visceral metastases. All three types of primary melanoma tumors exhibited strong β2-AR immunoreactivity in the tumor cells (9/10 cases) (Table 1). The staining was homogeneous and present both cytoplasmically as well as on the plasma membrane (Fig. 6). The metastases gave a similarly strong, homogeneous pattern of staining for both lymph nodes as well as visceral metastases (9/10 cases; not shown).
Table 1
Table 1
The presence of β1- and β2-AR in tumor cells within melanoma tumor biopsies.
Figure 6
Figure 6
A case of primary superficial-spreading melanoma illustrates intense β2-AR cytoplasmic/membrane immunoreactivity within the balls of melanoma cells (arrows) occupying the dermal/epidermal junction. The overlying epidermis and underlying dermis (more ...)
This staining was not apparent in negative control slides wherein no primary or secondary antibodies were applied (not shown). As a follow up, we examined melanoma biopsies for β1-AR expression and observed 6/10 of primary melanoma cases and 8/10 of metastatic melanoma cases were positive for the receptor (Table 1).
In this study, we examined the effect of NE on the expression of factors important in melanoma tumor progression. We found that exposure of the human melanoma tumor cell line, C8161, to NE resulted in the induction of VEGF, IL-8, and IL-6 protein levels. This NE-dependent effect was not as strong in the 1174MEL and Me18105 cell lines as compared to the C8161 cell line. We show that the upregulation of the levels of these proteins in culture supernatants is not due to a stimulation of cell proliferation. In contrast to the observed difference in the NE-dependent modulation of protein levels in the three cell lines, we show that NE efficiently upregulated VEGF, IL-8, and IL-6 mRNA levels in all three cell lines. We further show that the expression of the three genes in C8161 cells is mainly due to increased de novo transcription. We show that C8161, 1174MEL and Me18105 cells expressed different levels of the β1- and β2-AR proteins and the mRNA that encode them (the ADRB1 and ADRB2, respectively). It is currently not known what accounts for the difference in the transcriptional and translational effects of NE on these three proteins. Evidence supporting the role of β-ARs in the NE-dependent effect is provided by the results showing that propranolol completely inhibited the NE-dependent upregulation of gene expression in all three cell lines, and that the agonists dobutamine and terbutaline stimulated VEGF, IL-8, and IL-6 gene expression in C8161 cells.
The activation of the hypothalamic-pituitary-adrenal (HPA) and the SAM axes that results in an increase of stress hormone levels have been shown to induce immune dysregulation significant enough to produce health outcomes, such as the slowing of wound healing (Glaser and Kiecolt-Glaser, 2005; Kiecolt-Glaser et al., 1995; Mercado et al., 2002). Stress-associated immune dysregulation can upregulate the production of proinflammatory cytokines, such as IL-1, TNF-α, and IL-6 (Glaser and Kiecolt-Glaser, 2005; Gomez-Merino et al., 2005; Johnson et al., 2005; Kiecolt-Glaser et al., 2005; Segerstrom and Miller, 2004). Inflammation has been linked to a significant percentage of cancers suggesting another alternative whereby stress could be a co-factor for modulating the growth and progression of tumor cells. Stress-induced changes in the cellular immune response results in decreased antigen-specific T-cell and natural killer (NK) cell responses and have implications for the immune response to immunogenic tumors (Glaser and Kiecolt-Glaser, 2005; Padgett and Glaser, 2003). Studies have also implicated stress-related effects on immune function as having an influence on tumor progression (Ben-Eliyahu, 2003; Goldfarb and Ben-Eliyahu, 2007; Lamkin et al., 2008; Reiche et al., 2004; Saul et al., 2005). The data obtained in this study support the hypothesis of an alternative pathway linking stress with cancer progression via effects on other biological processes involving the SAM axis (Antoni et al., 2006; Reiche et al., 2004; Saul et al., 2005; Thaker et al., 2007).
Work by Entschladen and others have indicated a role for catecholamines in tumor progression (Entschladen et al., 2004). For example, catecholamines have been shown to promote the migration of breast and colon cancer cells in vitro (Drell et al., 2003; Masur et al., 2001) and the metastasis of human PC-3 prostate cancer cells in nude mice (Palm et al., 2006), effects that could be inhibited by the addition of β-blockers. The data from this study suggest that NE may further enhance tumor progression by stimulating the process of angiogenesis. The processes promoted by the NE-dependent upregulation of VEGF, IL-8, and IL-6 expression are yet to be fully understood. However, these factors have been implicated in several processes associated with melanoma tumor progression including the angiogenic process (Mahabeleshwar and Byzova, 2007). For example, it has been shown that VEGF released by melanoma cells is an important mediator of neo-vascularization and has been shown to be a marker for melanoma progression (Löffek et al., 2006; Osella-Abate et al., 2002). In addition, serum levels of IL-6 have been associated with advanced stages of the disease, the ability to discriminate progressive from non-progressive disease, and have been used as a serum marker for monitoring response to chemotherapy and survival. Furthermore, IL-8 and IL-6 are released in the culture supernatants of highly invasive melanoma cells (Bar-Eli, 1999; Payne and Cornelius, 2002). Both these factors are involved in angiogenesis by either directly stimulating the proliferation and differentiation of endothelial cells or by inducing the production of additional factors in other cells (Bar-Eli, 1999).
Since the recent studies by Sood and others suggest that the NE-dependent effects on the growth of ovarian tumor cells in nude mice are mediated through the tumor cell cAMP-PKA signaling pathway (Thaker et al., 2006), we focused on this signaling pathway in our study. Our results show that isoproterenol is a potent inducer of VEGF, IL-8 and IL-6 gene expression in C8161 cells supporting the role of β-ARs in this pathway. In addition, our results show that the adenylate cyclase agonist forskolin stimulated the expression of the VEGF, IL-8 and IL-6 genes while the cAMP analogs 8-CPT and 6-Bnz-cAMP did not efficiently stimulate the expression of the three genes. Furthermore, our observation that H-89 effectively inhibited the NE-dependent upregulation of IL-8 and IL-6 mRNA levels in C8161 cells while PKI did not can be explained by the fact that H-89 has inhibitory effects on the activities of protein kinase G (PKG) and PKC as well (Chijiwa et al., 1990; Hidaka and Kobayashi, 1992). These observations suggest that the cAMP-PKA signaling pathway may play a limited role in mediating these effects and further elucidation of the signaling pathway involved has yet to be addressed.
It is of interest that we are seeing differences in the expression of pro-angiogenic proteins in cells derived from different kinds of tumors in spite of the fact that the tumor cells express β-ARs and that the these proteins can be induced by NE in each study (Yang et al., 2008; Yang et al., 2006). Although NPC, multiple myeloma-derived, and melanoma cell lines all express immunoreactive bands of the same relative molecular weights in Western blots detecting β1- and β2-ARs, the abundance of the specific bands differed among these types of cancers. We still do not know how these differences play a part in their varying responses to NE. Our data add to the growing literature showing that the modulatory effects of psychological factors may have important clinical relevance and may lead to new approaches for treating cancer.
Consistent with our NPC study, we also observed the expression of β2-AR on tumor cells in a majority of melanoma biopsies supporting the possible clinical relevance of our in vitro results. It is important to note that in this study we examined different classes of melanoma, i.e., primary melanoma (nodular, superficial spreading and desmoplastic) and metastatic melanoma (lymph node and visceral metastasis). We found that these classes of melanoma express the β1-AR as well. That a majority of the melanoma tumors we examined expressed β-ARs supports our hypothesis that melanoma tumor cells at various stages of the disease have the potential to respond to NE.
Derived from neural crest stem cells, human malignant melanoma is one of the most deadly of human neoplasms, exhibiting aggressive metastatic behavior even when its primary tumor is very small (Safarians et al., 1996). Whereas most human cancers metastasize when they reach a size of 1 cm diameter, melanomas can metastasize when they are only 1 mm in size demonstrating a 1000 fold increase in inherent metastatic potential (Barsky et al., 1997). Our traditional methods of staging and predicting distal metastasis and melanoma recurrence are based on measurements of tumor thickness in the skin and presence of tumor in regional lymph nodes but these prognostic markers fall short in the majority of cases where the likelihood of tumor recurrence and metastasis remains indeterminate (Balch et al., 2001). Although a number of genetic abnormalities have been identified in human melanomas including significant alterations involving the BRAFpathway (Haluska et al., 2007), to date no molecular subclassification scheme has improved upon the prognostic information imparted by thickness alone (Palmieri et al., 2007). Since it can be assumed that the overall tumor burden at presentation is low in the majority of cases, it is likely that host rather than tumoral factors alone regulate recurrence or cure. Stress may be one important host cofactor. Certainly the presence of adrenergic receptors and signaling in human melanoma cell lines and cases of human melanoma support this hypothesis.
Our data support the hypothesis that the stress hormone, NE, can stimulate the aggressive potential of melanoma tumor cells by inducing the release of proteins, including VEGF, IL-8, and IL-6. The role(s) that psychological factors may play in tumor progression is not fully understood but the connection between the HPA and SAM axes that have been described by our laboratory and others may add to our understanding of the role of psychological stressors on the progression of some tumors. The fact that these three factors are upregulated in C8161, a cell line known for its highly metastatic phenotype, and not to the same extent in 1174MEL and Me18105, supports the hypothesis that different tumor cell populations may respond differently to the release of stress hormones and that stress can be a co-factor for the progression of a highly metastatic cancer. It is not known whether 1174MEL and Me18105 produce metastatic tumors in a nude mouse. To our knowledge, this is the first report to suggest that stress-related activation of the SAM axis may have a role in human melanoma tumor progression.
Acknowledgments
We thank Dr. Christophe Plass for providing the C8161 cells, and Dr. Soldano Ferrone, Dr. William Carson III and Dr. Greg Lesinski for the 1174MEL and Me18105 cells. We thank Susie Jones and Cheryl Reeder (Pathology Core Facility, The Ohio State University), and Dr. Jiayuh Lin and Brian Hutzen for technical assistance. We also thank Caitlin McDonnell for her critical reading of the manuscript and helpful suggestions. This study was supported in part by NCI CA100243 and The Gilbert and Kathryn Mitchell Endowment to RG, NCI CA100243-01A2S1 to EVY, and The Ohio State University Comprehensive Cancer Center Core Grant CA16058 (NCI).
Footnotes
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
  • Ader R, editor. Psychoneuroimmunology. Elsevier Academic Press; Boston: 2007.
  • Antoni MH, Lutgendorf SK, Cole SW, Dhabhar FS, Sephton SE, McDonald PG, Stefanek M, Sood AK. The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nature Reviews. Cancer. 2006;6:240–248. [PMC free article] [PubMed]
  • Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, Liu PY, Lyman GH, Morabito A. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2001;19:3622–3634. [PubMed]
  • Bar-Eli M. Role of interleukin-8 in tumor growth and metastasis of human melanoma. Pathobiology. 1999;67:12–18. [PubMed]
  • Barsky SH, Sternlicht MD, Safarians S, Nguyen M, Chin K, Stewart SD, Hiti AL, Gray JW. Evidence of a dominant transcriptional pathway which regulates an undifferentiated and complete metastatic phenotype. Oncogene. 1997;15:2077–2091. [PubMed]
  • Ben-Eliyahu S. The promotion of tumor metastasis by surgery and stress: immunological basis and implications for psychoneuroimmunology. Brain, Behavior, and Immunity. 2003;17(Suppl 1):S27–36. [PubMed]
  • Canada AL, Fawzy NW, Fawzy FI. Personality and disease outcome in malignant melanoma. Journal of Psychosomatic Research. 2005;58:19–27. [PubMed]
  • Chijiwa T, Mishima A, Hagiwara M, Sano M, Hayashi K, Inoue T, Naito K, Toshioka T, Hidaka H. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. The Journal of Biological Chemistry. 1990;265:5267–5272. [PubMed]
  • Drell TL, Joseph J, Lang K, Niggemann B, Zaenker KS, Entschladen F. Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Research and Treatment. 2003;80:63–70. [PubMed]
  • Entschladen F, Drell TL, Lang K, Joseph J, Zaenker KS. Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters. The Lancet Oncology. 2004;5:254–258. [PubMed]
  • Fawzy FI, Canada AL, Fawzy NW. Malignant melanoma: effects of a brief, structured psychiatric intervention on survival and recurrence at 10-year follow-up. Archives of General Psychiatry. 2003;60:100–103. [PubMed]
  • Fawzy FI, Fawzy NW, Hyun CS, Elashoff R, Guthrie D, Fahey JL, Morton DL. Malignant melanoma: Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Archives of General Psychiatry. 1993;50:681–689. [PubMed]
  • Gimbrone MA, Jr, Leapman SB, Cotran RS, Folkman J. Tumor dormancy in vivo by prevention of neovascularization. The Journal of Experimental Medicine. 1972;136:261–276. [PMC free article] [PubMed]
  • Glaser R, Kiecolt-Glaser JK. Stress-induced immune dysfunction: implications for health. Nature Reviews Immunology. 2005;5:243–251. [PubMed]
  • Goldfarb Y, Ben-Eliyahu S. Surgery as a risk factor for breast cancer recurrence and metastasis: mediating mechanisms and clinical prophylactic approaches. Breast Disease. 2007;26:99–114. [PubMed]
  • Gomez-Merino D, Drogou C, Chennaoui M, Tiollier E, Mathieu J, Guezennec CY. Effects of combined stress during intense training on cellular immunity, hormones and respiratory infections. Neuroimmunomodulation. 2005;12:164–172. [PubMed]
  • Haluska F, Pemberton T, Ibrahim N, Kalinsky K. The RTK/RAS/BRAF/PI3K Pathways in Melanoma: Biology, Small Molecule Inhibitors, and Potential Applications. Seminars in oncology. 2007;34:546–554. [PubMed]
  • Hasegawa H, Saiki I. Psychosocial stress augments tumor development through beta-adrenergic activation in mice. Japanese Journal of Cancer Research: Gann. 2002;93:729–735. [PubMed]
  • Hicklin DJ, Wang Z, Arienti F, Rivoltini L, Parmiani G, Ferrone S. beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. The Journal of Clinical Investigation. 1998;101:2720–2729. [PMC free article] [PubMed]
  • Hidaka H, Kobayashi R. Pharmacology of protein kinase inhibitors. Annual Review of Pharmacology and Toxicology. 1992;32:377–397. [PubMed]
  • Johnson JD, Campisi J, Sharkey CM, Kennedy SL, Nickerson M, Greenwood BN, Fleshner M. Catecholamines mediate stress-induced increases in peripheral and central inflammatory cytokines. Neuroscience. 2005;135:1295–1307. [PubMed]
  • Kiecolt-Glaser JK, Loving TJ, Stowell JR, Malarkey WB, Lemeshow S, Dickinson SL, Glaser R. Hostile marital interactions, proinflammatory cytokine production, and wound healing. Archives of General Psychiatry. 2005;62:1377–1384. [PubMed]
  • Kiecolt-Glaser JK, Marucha PT, Malarkey WB, Mercado AM, Glaser R. Slowing of wound healing by psychological stress. Lancet. 1995;346:1194–1196. [PubMed]
  • Kruk J, Aboul-Enein HY. Psychological stress and the risk of breast cancer: a case-control study. Cancer Detection and Prevention. 2004;28:399–408. [PubMed]
  • Lamkin DM, Lutgendorf SK, McGinn S, Dao M, Maiseri H, DeGeest K, Sood AK, Lubaroff DM. Positive psychosocial factors and NKT cells in ovarian cancer patients. Brain, Behavior, and Immunity. 2008;22:65–73. [PMC free article] [PubMed]
  • Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–408. [PubMed]
  • Löffek S, Zigrino P, Steiger J, Kurschat P, Smola H, Mauch C. Melanoma cell-derived vascular endothelial growth factor induces endothelial tubulogenesis within fibrin gels by a metalloproteinase-mediated mechanism. European Journal of Cell Biology. 2006;85:1167–1177. [PubMed]
  • Lutgendorf SK, Cole S, Costanzo E, Bradley S, Coffin J, Jabbari S, Rainwater K, Ritchie JM, Yang M, Sood AK. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clinical Cancer Research. 2003;9:4514–4521. [PubMed]
  • Mahabeleshwar GH, Byzova TV. Angiogenesis in Melanoma. Seminars in oncology. 2007;34:555–565. [PMC free article] [PubMed]
  • Masur K, Niggemann B, Zanker KS, Entschladen F. Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Research. 2001;61:2866–2869. [PubMed]
  • Mercado AM, Quan N, Padgett DA, Sheridan JF, Marucha PT. Restraint stress alters the expression of interleukin-1 and keratinocyte growth factor at the wound site: an in situ hybridization study. Journal of neuroimmunology. 2002;129:74–83. [PubMed]
  • Metcalfe C, Davey Smith G, Macleod J, Hart C. The role of self-reported stress in the development of breast cancer and prostate cancer: a prospective cohort study of employed males and females with 30 years of follow-up. European Journal of Cancer (Oxford, England: 1990) 2007;43:1060–1065. [PubMed]
  • Nilsson MB, Langley RR, Fidler IJ. Interleukin-6, Secreted by Human Ovarian Carcinoma Cells, Is a Potent Proangiogenic Cytokine. Cancer Res. 2005;65:10794–10800. [PMC free article] [PubMed]
  • Osella-Abate S, Quaglino P, Savoia P, Leporati C, Comessatti A, Bernengo MG. VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course. Melanoma Research. 2002;12:325–334. [PubMed]
  • Padgett DA, Glaser R. How stress influences the immune response. Trends in immunology. 2003;24:444–448. [PubMed]
  • Palm D, Lang K, Niggemann B, Drell TLt, Masur K, Zaenker KS, Entschladen F. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. International Journal of Cancer. 2006;118:2744–2749. [PubMed]
  • Palmieri G, Casula M, Sini MC, Ascierto PA, Cossu A. Issues affecting molecular staging in the management of patients with melanoma. Journal of Cellular and Molecular Medicine. 2007;11:1052–1068. [PubMed]
  • Payne AS, Cornelius LA. The role of chemokines in melanoma tumor growth and metastasis. The Journal of Investigative Dermatology. 2002;118:915–922. [PubMed]
  • Rabin BS. Stress, immune function, and health: the connection. Wiley-Liss; New York: 1999.
  • Reiche EMV, Nunes SOV, Morimoto HK. Stress, depression, the immune system, and cancer. The Lancet Oncology. 2004;5:617–625. [PubMed]
  • Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA. Loss of Functional Beta2-Microglobulin in Metastatic Melanomas From Five Patients Receiving Immunotherapy. Journal of the National Cancer Institute. 1996;88:100–108. [PMC free article] [PubMed]
  • Riley V. Mouse mammary tumors: alteration of incidence as apparent function of stress. Science. 1975;189:465–467. [PubMed]
  • Safarians S, Sternlicht MD, Freiman CJ, Huaman JA, Barsky SH. The primary tumor is the primary source of metastasis in a human melanoma/SCID model. Implications for the direct autocrine and paracrine epigenetic regulation of the metastasis process. International Journal of Cancer. 1996;66:151–158. [PubMed]
  • Salahpour A, Bonin H, Bhalla S, Petaja-Repo U, Bouvier M. Biochemical characterization of beta2-adrenergic receptor dimers and oligomers. Biological Chemistry. 2003;384:117–123. [PubMed]
  • Saul AN, Oberyszyn TM, Daugherty C, Kusewitt D, Jones S, Jewell S, Malarkey WB, Lehman A, Lemeshow S, Dhabhar FS. Chronic Stress and Susceptibility to Skin Cancer. Journal of the National Cancer Institute. 2005;97:1760–1767. [PMC free article] [PubMed]
  • Segerstrom SC, Miller GE. Psychological stress and the human immune system: a meta-analytic study of 30 years of inquiry. Psychological Bulletin. 2004;130:601–630. [PMC free article] [PubMed]
  • Sood AK, Bhatty R, Kamat AA, Landen CN, Han L, Thaker PH, Li Y, Gershenson DM, Lutgendorf S, Cole SW. Stress Hormone-Mediated Invasion of Ovarian Cancer Cells. Clinical Cancer Research. 2006;12:369–375. [PMC free article] [PubMed]
  • Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of vascular endothelial growth factors. Cardiovascular Research. 2005;65:550–563. [PubMed]
  • Temoshok L, Heller BW, Sagebiel RW, Blois MS, Sweet DM, DiClemente RJ, Gold ML. The relationship of psychosocial factors to prognostic indicators in cutaneous malignant melanoma. Journal of Psychosomatic Research. 1985;29:139–153. [PubMed]
  • Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nature Medicine. 2006;12:939. [PubMed]
  • Thaker PH, Lutgendorf SK, Sood AK. The neuroendocrine impact of chronic stress on cancer. Cell Cycle (Georgetown, Tex) 2007;6:430–433. [PubMed]
  • Welch DR, Bisi JE, Miller BE, Conaway D, Seftor EA, Yohem KH, Gilmore LB, Seftor RE, Nakajima M, Hendrix MJ. Characterization of a highly invasive and spontaneously metastatic human malignant melanoma cell line. International Journal of Cancer. 1991;47:227–237. [PubMed]
  • White V, English D, Coates H, Lagerlund M, Borland R, Giles G. Is cancer risk associated with anger control and negative affect? Findings from a prospective cohort study. Psychosomatic Medicine. 2007;69:667–674. [PubMed]
  • Yang EV, Donovan EL, Benson DM, Glaser R. VEGF is differentially regulated in multiple myeloma-derived cell lines by norepinephrine. Brain, Behavior, and Immunity. 2008;22:318–323. [PMC free article] [PubMed]
  • Yang EV, Sood AK, Chen M, Li Y, Eubank TD, Marsh CB, Jewell S, Flavahan NA, Morrison C, Yeh PE, Lemeshow S, Glaser R. Norepinephrine Up-regulates the Expression of Vascular Endothelial Growth Factor, Matrix Metalloproteinase (MMP)-2, and MMP-9 in Nasopharyngeal Carcinoma Tumor Cells. Cancer Research. 2006;66:10357–10364. [PubMed]
  • Yuan A, Chen JJW, Yao PL, Yang PC. The role of interleukin-8 in cancer cells and microenvironment interaction. Frontiers in Bioscience: a Journal and Virtual Library. 2005;10:853–865. [PubMed]